Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This is a prospective open label clinical trial in patients with advanced or metastatic liver
cancer to assess the clinical and biological activity of RAD001 (Everolimus) in conjunction
with Bevazicumab (Avastin). Approximately 36 patients will be enrolled.